Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | ACACB | O00763 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29499811 | 1.00 | PDE2A (0.48) | PDE2APARP10PARP15SCN9AACACB | |
| SCHEMBL29499785 | 0.83 | PARP10 (0.44) | PARP10PARP15SCN9AACACBFFAR4 | |
| SCHEMBL23040181 | 0.83 | PARP10 (0.44) | PARP10PARP15SCN9AACACBFFAR4 | |
| SCHEMBL21736840 | 0.82 | PARP10 (0.48) | PARP10PARP15SCN9AACACBACACA | |
| SCHEMBL16216193 | 0.78 | PDE2A (0.51) | PDE2AFFAR4 | |
| SCHEMBL10303249 | 0.77 | FFAR1 (0.39) | PARP10PARP15ACACB | |
| SCHEMBL10303240 | 0.77 | FFAR1 (0.39) | SCN9AACACB | |
| SCHEMBL21910441 | 0.76 | PARP15 (0.49) | PARP10PARP15ACACBACACA | |
| SCHEMBL12907074 | 0.76 | FFAR1 (0.38) | PARP10PARP15ACACB | |
| SCHEMBL14901056 | 0.75 | PARP10 (0.55) | PARP10PARP15SCN9AFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4021901-B1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-05 | — | — | US | disclosed |
| CN-114302884-B | Substituted pyridopyrimidinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-18 | — | — | US | disclosed |
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-02-21 | — | — | US | disclosed |
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-02-21 | — | — | US | disclosed |
| EP-4021901-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114302884-A | Substituted pyridopyrimidinone based compounds useful as T cell activators | 百时美施贵宝公司 | 2022-04-08 | — | — | CN | disclosed |
| WO-2021041588-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021041588-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2021-03-04 | — | — | US | disclosed |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | DGKZ, DGKA, DGKG | PDE2A 1693/4885PARP10 1518/4885PARP15 1689/4885 |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | PDE2A 1693/4885PARP10 1518/4885PARP15 1689/4885 |
| US-20240400563-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | PDE2A 1693/4885PARP10 1518/4885PARP15 1689/4885 |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | PDE2A 1704/4885PARP10 1713/4885PARP15 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.